FCCC LOGO Faculty Publications
Badar T , Hamadani M , Bachanova V , Maddocks KJ , Umyarova E , Chavez JC , Epperla N , Chhabra S , Xavier AC , Karmali R , Salhab M , Reddy N , Glenn MJ , Hernandez-Ilizaliturri FJ , Flowers CR , Evens AM , Zhou Z , Lansigan F , Barta SK , Cohen JB , Fenske TS , Costa LJ
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
Leuk Lymphoma. 2019 Apr;60(4) :940-946
Back to previous list
We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/- rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46-1.60, p = .64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20-1.44, p = .21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.
Badar, Talha Hamadani, Mehdi Bachanova, Veronika Maddocks, Kami J. Umyarova, Elvira Chavez, Julio C. Epperla, Narendranath Chhabra, Saurabh Xavier, Ana C. Karmali, Reem Salhab, Mohammed Reddy, Nishitha Glenn, Martha J. Hernandez-Ilizaliturri, Francisco J. Flowers, Christopher R. Evens, Andrew M. Zhou, Zheng Lansigan, Frederick Barta, Stefan K. Cohen, Jonathon B. Fenske, Timothy S. Costa, Luciano J. Xavier, Ana/0000-0002-3659-3798; Badar, Talha/0000-0003-1548-918X; Karmali, Reem/0000-0003-0984-4376; Bachanova, Veronika/0000-0002-9325-432X; Evens, Andrew/0000-0002-6900-1824 1029-2403 Leuk Lymphoma. 2019 Apr;60(4):940-946. doi: 10.1080/10428194.2018.1515944. Epub 2018 Oct 2.